Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Citi
QuintilesIMS
Chubb
Federal Trade Commission
McKinsey

Generated: September 16, 2019

DrugPatentWatch Database Preview

Patent: 9,938,356

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,938,356
Title:Binding molecules specific for CD73 and uses thereof
Abstract: The present disclosure provides anti-CD73 binding molecules, e.g., antibodies and antigen binding fragments thereof. Also provided are pharmaceutical formulations comprising the disclosed compositions, and methods for the diagnosis and treatment of diseases associated with CD73-expression, e.g., cancer. Such diseases can be treated, e.g., by direct therapy with the anti-CD73 binding molecules disclosed herein (e.g., naked antibodies or antibody-drug conjugates that bind CD73), by adjuvant therapy with other antigen-binding anticancer agents such as immune checkpoint inhibitors (e.g., anti-CTLA-4 and anti-PD-1 monoclonal antibodies), and/or by combination therapies where the anti-CD73 molecules are administered before, after, or concurrently with chemotherapy.
Inventor(s): Hay; Carl (Gaithersburg, MD), Sachsenmeier; Kris (Gaithersbrug, MD), Sult; Erin (Gaithersburg, MD), Huang; Qihui (Gaithersburg, MD), Pavlik; Peter (Gaithersburg, MD), Damschroder; Melissa (Gaithersburg, MD), Cheng; Li (Gaithersburg, MD), Diedrich; Gundo (Gaithersburg, MD), Rios-Doria; Jonathan (Gaithersburg, MD), Hammond; Scott (Gaithersburg, MD), Minter; Ralph (Cambridge, GB), Rust; Steve (Cambridge, GB), Guillard; Sandrine (Cambridge, GB), Hollingsworth; Robert (Gaithersburg, MD), Jermutus; Lutz (Cambridge, GB), Durham; Nicholas (Gaithersburg, MD), Leow; Ching Ching (Gaithersburg, MD), Antonysamy; Mary (Gaithersburg, MD), Geoghegan; James (Gaithersburg, MD), Lu; Xiaojun (Gaithersburg, MD), Rosenthal; Kim (Gaithersburg, MD)
Assignee: MEDIMMUNE LIMITED (Cambridge, GB)
Application Number:14/936,233
Patent Claims:see list of patent claims

Details for Patent 9,938,356

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Bristol Myers Squibb YERVOY ipilimumab INJECTABLE; INJECTION 125377 001 2011-03-25   Try a Free Trial 2038-10-17 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Merck
Boehringer Ingelheim
Express Scripts
Federal Trade Commission
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.